Key clinical research terms explained, from Site CTMS to ALCOA++.
A Site CTMS is a platform designed to manage the day-to-day operations of a clinical research site. It centralizes protocols, patients, scheduling, regulatory documentation, pharmacy, laboratory, finances, tasks, and site metrics. Unlike a sponsor- or CRO-oriented CTMS, it focuses on the site's operational needs and on data traceability from the point where the data originates.
A Clinical Trial Management System is software used to plan, manage, and oversee clinical trials. Depending on the solution, it may be designed for sponsors, CROs, or research sites and may cover study tracking, milestones, documents, sites, visits, budgets, and performance. Because CTMS is a broad term, it is important to specify whether the system serves a sponsor, a CRO, or the research site itself.
eSource refers to the direct capture of clinical source data in electronic form, without first relying on paper records. It may include a protocol-driven electronic health record, digital forms, and other original records created during patient care or a study visit. Its value lies in improving data quality, availability, and traceability from the moment the data is generated.
The electronic Investigator Site File is the digital version of the regulatory file that stores essential study documentation at the research site. It brings together site, protocol, and staff documents, controls versions, signatures, and expiration dates, and supports monitoring, audits, and inspections. A well-managed eISF should make it possible to show which document was current, who acted on it, and when.
An Electronic Data Capture system is primarily used to collect and manage trial data reported to the sponsor, usually through eCRFs. It supports data validation, queries, and centralized study review. It does not replace the site's full operational management and is not necessarily the source record; it commonly receives selected data that were first generated and documented at the site.
An electronic Case Report Form is the digital form through which a site reports protocol-required participant data to the sponsor. It defines study-specific fields, rules, and validations. An eCRF does not necessarily contain the full medical record or the site's complete operation; it captures the subset of information required for trial analysis.
IWRS and IRT refer to interactive systems used to manage processes such as participant randomization, treatment assignment, and investigational product supply. These platforms are typically part of the sponsor's technology ecosystem. They complement the Site CTMS, which organizes the site's daily execution and may document the related tasks and evidence.
Clinical trial interoperability is the ability of different systems to exchange and use information consistently, securely, and traceably. It may connect the site's operational environment with EDC, eCRF, IRT, ERP, or other platforms while preserving data context and integrity. It is not only a technical integration; it also requires compatible processes, identifiers, and responsibilities.
Veeva EDC is the electronic data capture application through which sponsors and CROs collect, review, and process trial information reported by sites. During study execution, it supports eCRFs, validations, queries, and data quality controls. In an integration scenario, Brainmart could structure data at the source as eSource and transfer the required information to the EDC, reducing manual re-entry without replacing the sponsor's official system.
Veeva CTMS is an enterprise system for managing and overseeing clinical trials from the sponsor or CRO perspective. It centralizes information about studies, countries, sites, milestones, monitoring, and performance. It differs from a Site CTMS because its primary focus is sponsor portfolio management and oversight, while Brainmart focuses on the research site's day-to-day operational execution.
Veeva SiteVault brings together digital solutions for research sites, including capabilities for eISF and site operations. Its market presence makes it relevant to compare scope, users, and use cases when evaluating site technology. Brainmart should position itself through its comprehensive Site CTMS proposition, operational fit, and ability to integrate with the sponsor's ecosystem.
eSource-to-EDC integration connects the system where clinical data originate with the EDC used by the sponsor. Its purpose is to transfer protocol-required information in a structured and controlled manner, avoiding repeated manual entry by the site team. For Brainmart, it represents the strategic bridge between site execution and platforms such as Veeva EDC.
Duplicate data entry occurs when the same clinical information must be manually recorded in more than one system, for example first in the site's source system and then in the sponsor's EDC. This process consumes time, creates rework, and increases the risk of inconsistencies. Connecting Brainmart as eSource with Veeva EDC aims to capture data once at the source and allow it to flow to the appropriate system.
A Veeva Product Partner is a company participating in Veeva's technology partner ecosystem to develop and maintain solutions that integrate, or are being prepared to integrate, with Veeva products. The program provides access to tools, training, best practices, and support. Scope should be communicated precisely: partner status does not automatically mean that every integration is certified; the partnership level, product area, and certification status determine what has been validated and what remains in progress.
An audit trail is a secure electronic record of actions performed on data or documents: who did what, when, and, when applicable, why. It makes it possible to reconstruct the history of a record's creation, modification, signature, or deletion without overwriting prior evidence. It is a key component of traceability and regulatory review.
FDA 21 CFR Part 11 is the U.S. regulation that sets criteria under which certain electronic records and electronic signatures can be considered trustworthy and equivalent to paper records and handwritten signatures. In clinical research systems, it is associated with access controls, system validation, audit trails, record retention, and linking a signature to the signed record.
Good Clinical Practice is an international ethical and scientific standard for designing, conducting, recording, and reporting trials involving human participants. It aims to protect participants' rights, safety, and well-being and to ensure that trial results are credible. ICH-GCP also defines responsibilities for sponsors, investigators, monitors, and other study parties.
ALCOA++ is a set of principles used to assess data integrity. Records should be attributable, legible, contemporaneous, original, and accurate, as well as complete, consistent, enduring, and available. In clinical research, these principles help ensure that each data point can be understood, traced, and maintained as evidence throughout its lifecycle.
Data integrity is the degree to which information remains complete, consistent, accurate, and reliable throughout its lifecycle. It covers how data are captured, changed, transferred, reviewed, retained, and retrieved. In a clinical trial, strong data integrity makes it possible to show that results are supported by verifiable records and that every change is documented.
Source data are original information, or certified copies of that information, documenting observations, activities, and results needed to reconstruct and evaluate a clinical trial. They may originate in medical records, laboratory results, pharmacy records, images, devices, or electronic forms. They should retain enough context to verify how and when they were generated.
An electronic signature is a set of data associated with an electronic record that identifies the signer and expresses an action or intent, such as approval, review, or accountability. In a regulated environment, it should be linked to the record, protected against unauthorized use, and accompanied by information such as the signer's identity, date, time, and meaning of the signature.
Audit readiness and inspection readiness describe a site's ability to demonstrate at any time that a study was conducted and documented in a controlled manner. This requires current and complete documents, traceable data, clear roles, managed findings, and rapid access to evidence. It is not a last-minute exercise but an ongoing operational state.
Study start-up is the stage covering the activities required for a clinical trial to begin at a site. It includes feasibility, site selection, contracts and budget, regulatory documentation, approvals, operational setup, training, and activation. Its efficiency depends on coordinating multiple functions and maintaining visibility over requirements, owners, versions, and dates.
Feasibility is the assessment used to determine whether a site can successfully conduct a protocol. It examines patient population, investigator experience, resources, infrastructure, timelines, competing studies, and operational capacity. A complete, consistent, and traceable response helps the sponsor or CRO compare sites and make selection decisions.
Site activation is the milestone at which a research site is authorized and ready to begin study activities in accordance with sponsor, CRO, and applicable regulatory requirements. It usually requires approvals, contracts, essential documents, training, supply availability, and confirmation that operational processes are ready.
First Patient In is the milestone marking the inclusion of the first participant in a trial or at a specific site, depending on the study definition. It is used to measure how quickly a protocol moves from activation into actual execution. The date should be interpreted together with the operational definition being used, such as consent, screening, or enrollment.
Remote monitoring allows authorized monitors to securely review study documents, data, and evidence from a distance. It may include access management, comments, findings, response tracking, and an audit trail. It does not eliminate every on-site visit, but it can reduce on-site review work and support more continuous, risk-based oversight.
Principal Investigator oversight is the PI's responsibility to maintain appropriate supervision over trial conduct at the site. It includes ensuring proper delegation, training, protocol compliance, participant protection, and timely review of relevant information. Technology can provide visibility and evidence, but it does not transfer or replace the PI's responsibility.
A protocol deviation is a departure from the approved protocol, study procedures, or applicable requirements. It should be identified, documented, assessed, and managed according to its impact on participant safety and data integrity. Trend analysis helps prevent recurrence and strengthen site processes.
Drug accountability is the documented control of an investigational product from receipt through dispensing, return, reconciliation, or destruction. It includes quantities, batches, dates, conditions, participants, and responsible personnel. Its purpose is to show that the product was stored and used according to the protocol and that any discrepancy can be investigated.
A clinical research site is the organization where trial activities involving participants are conducted under the responsibility of a Principal Investigator. It may be a hospital, clinic, academic institution, or independent site. It recruits and cares for participants, generates source data, manages investigational product, and retains the documentation needed to demonstrate compliance.
A sponsor is the person, company, institution, or organization that takes responsibility for initiating, managing, and financing a clinical trial. The sponsor defines the protocol and oversight framework, selects or contracts operational parties, and must ensure that the study meets applicable requirements. Tasks may be delegated to a CRO, but the sponsor retains oversight responsibilities.
A Contract Research Organization is hired by a sponsor to perform one or more trial-related functions, such as operational management, site selection, monitoring, data management, or regulatory support. It acts as a specialized operational arm, although its specific scope depends on the contract. Efficient collaboration with sites requires timely information, clear processes, and traceable evidence.
Clinical trial KPIs are metrics used to assess speed, quality, compliance, and operational capacity. At a site they may include start-up time, enrollment rate, visit completion, deviations, response times, document expirations, and protocol-level financial status. To be useful, KPIs need consistent definitions and must be based on complete, traceable data.
Site performance is the assessment of a research site's execution, quality, and compliance based on defined metrics. It may consider activation speed, enrollment, retention, document quality, deviations, productivity, and responsiveness to findings. Comparable historical information helps the site identify improvements and demonstrate capacity to sponsors and CROs.
Clinical trial digitalization is the transformation of manual, fragmented, or paper-based processes into controlled electronic workflows. It is not simply document scanning; it involves structuring data, automating tasks, managing access, retaining audit trails, connecting functions, and measuring performance. At the site, it can integrate coordination, documentation, pharmacy, laboratory, finances, and monitoring.
The Principal Investigator is the professional responsible for conducting the clinical trial at the research site. The PI oversees the study team, protects participants' rights and safety, ensures protocol compliance, and reviews relevant clinical information. Qualified tasks may be delegated, but the PI remains responsible for trial conduct at the site.
A Sub-Investigator is a clinical team member authorized to perform relevant medical or scientific trial activities under the supervision of the Principal Investigator. Responsibilities should be documented in the delegation log and supported by appropriate training and experience. The role does not replace the PI's overall accountability for the study.
A Clinical Research Coordinator organizes the protocol's day-to-day execution at the site. The CRC coordinates visits, documentation, participant communication, team tasks, schedules, and responses to monitors. The role connects medical, regulatory, administrative, pharmacy, and laboratory functions, making the CRC a primary user of a Site CTMS.
A Clinical Research Associate, or monitor, verifies that the trial is conducted in accordance with the protocol, Good Clinical Practice, and applicable procedures. The CRA reviews data, documents, consent, investigational product, and finding resolution, and serves as an operational link between the sponsor or CRO and the site. Monitoring may be on-site, remote, or hybrid.
A Site Regulatory Coordinator manages essential trial documentation at the research site. The role controls versions, signatures, expiration dates, submissions, approvals, and regulatory correspondence, and keeps the eISF current. The coordinator also prepares evidence for monitoring, audits, and inspections and follows up with the PI, sponsor, and CRO.
A Clinical Research Pharmacist manages investigational product in accordance with the protocol and site procedures. The role controls receipt, storage, temperature, inventory, preparation, dispensing, return, and destruction while maintaining complete and traceable records. The pharmacist works closely with the PI, coordinator, and monitor.
Clinical trial monitoring is the systematic oversight of study conduct and documentation. It aims to confirm participant protection, data reliability, and compliance with the protocol, GCP, and applicable requirements. It may combine on-site, remote, and centralized review according to the monitoring plan and study risk.
A Site Monitoring Visit is a planned review in which the monitor assesses trial progress, documentation, and compliance at a research site. It may cover informed consent, source data, eCRFs, investigational product, regulatory files, and previous action items. Results are documented in a report and may generate follow-up actions.
Source Data Verification is the comparison of data reported in the eCRF or EDC with the corresponding source evidence to confirm accuracy and consistency. Its scope may vary according to the protocol, monitoring plan, and risk-based approach. Traceable eSource makes review easier and reduces time spent locating documentation.
Risk-Based Monitoring is an approach that focuses oversight on the data, processes, and sites with the greatest potential impact on participant safety and study quality. It combines indicators, centralized review, and targeted activities to prioritize resources. Timely information and consistent metrics are needed to detect early signals.
A monitoring finding is a documented observation about a discrepancy, non-compliance issue, risk, or incomplete evidence identified during study review. It should be clearly described, assigned to an owner, and tracked through resolution. Trend analysis helps identify recurring problems and define preventive actions.
Corrective and Preventive Action is a structured process used to correct the cause of an identified problem and prevent recurrence. It includes root cause analysis, defined actions, owners, deadlines, implementation evidence, and effectiveness checks. In clinical research, a CAPA may arise from deviations, findings, audits, or quality trends.
A clinical data query is a request for clarification or correction raised when data reported in the EDC are missing, inconsistent, out of range, or require verification. The site must review the source evidence and provide a documented response. Structured capture at the source and a stronger connection between eSource and EDC can reduce inconsistencies and shorten query resolution cycles.
Data reconciliation is the process of comparing information from different systems or sources to identify and resolve discrepancies. It may involve eSource, EDC, laboratory, RTSM, safety, or other environments. When data transfer is automated and uses consistent identifiers and rules, manual comparison work is reduced and dataset reliability improves.
Protocol management centralizes the operational information for each study, including the current version, team, schedule, visits, tasks, documents, milestones, and overall status. In Brainmart, it acts as the backbone connecting patients, scheduling, pharmacy, laboratory, regulatory, and financial workflows under protocol-specific rules.
This module organizes the identification, contact, and initial assessment of potential participants before formal screening. It can record preliminary criteria, recruitment sources, candidate status, exclusion reasons, and follow-up. A structured workflow helps improve conversion rates and measure recruitment performance by protocol.
The clinical trial pharmacy module controls investigational product from receipt through dispensing, return, or destruction. It records inventory, batches, expiration dates, conditions, movements, and responsible users, producing traceable logs by protocol and participant. Integration with visits and patient records helps reduce errors and inventory discrepancies.
This module organizes laboratory kits, samples, and tasks associated with each protocol and visit. It can record receipt, inventory, expiration dates, preparation, collection, processing, storage, shipment, and responsible users. Traceability makes it possible to reconstruct each sample's journey and detect pending actions or deviations early.
Regulatory document management centralizes the site's essential documents and controls versions, signatures, expiration dates, status, and access. In Brainmart, it works with the eISF and start-up workflows to keep evidence current and available during monitoring, audits, and inspections. Alerts help prevent missing or expired documents.
Clinical trial financial management tracks budgets, completed visits, billable tasks, expenses, payments, and settlements with sponsors or CROs. By connecting clinical activity with administration, the site can identify unbilled services, reconcile payments, and analyze protocol-level profitability.
Adverse event management structures the recording, assessment, follow-up, and documentation of medical events occurring during a study. Records should retain dates, seriousness, causality, actions, outcome, and required notifications according to the protocol and applicable procedures. Traceability helps demonstrate timely review and response.
Business Intelligence dashboards turn site operational data into indicators for recruitment, visits, compliance, findings, regulatory timelines, and financial status. The Oversight module can provide controlled visibility to sponsors and CROs when authorized by the site, without allowing third parties to modify operations or source records.
This module organizes site users, roles, permissions, schedules, resources, and business units from a single control panel. It supports segmented access between care and research areas, blinded or unblinded profiles, and centralized operational alerts, professional availability, and master data required for daily execution.
A protocol-driven electronic health record is designed to document patient care within a clinical trial according to protocol requirements. It structures clinical notes, physical examinations, vital signs, eligibility criteria, treatments, compliance, and adverse events while retaining source-data traceability and version changes related to amendments.
A Site CTMS (Clinical Trial Management System) is the research center's internal management system: it coordinates visits, patients, pharmacy, laboratory, regulatory documentation and administration in a single traceable environment.
eSource is the recording of clinical data directly in electronic format as the original source. Brainmart's protocolarized EHR is the tool that captures that source data in a structured, auditable way for each protocol.
It is the data integrity principle: Attributable, Legible, Contemporaneous, Original, Accurate, plus Complete, Consistent, Enduring and Available. Brainmart is designed to meet these criteria natively.
We use cookies to improve your experience and remember your language. See our Cookie Policy.
